Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.
Gliomas account for the highest cases of primary brain malignancies. Whereas previous studies have demonstrated the roles of CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) in various cancer types, its functions in lower grade gliomas (LGGs) remain elusive. This study aimed to profile the expression and functions of CKS2 in LGG. Multiple online databases such as The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), Gene Expression Profiling Interactive Analysis 2nd edition (GEPIA2), Tumor Immune Estimation Resource 2nd edition (TIMER2.0) as well as Gene Expression Omnibus (GEO) were used in this study. Immunohistochemistry (IHC) was performed to evaluate CKS2 protein expression. Our data demonstrated upregulation of CKS2 in LGG tissues at both mRNA and protein level, especially in grade III gliomas. Similarly, there was increased expression of CKS2 in isocitrate dehydrogenase 1 (IDH1) wildtype gliomas. In addition, increased DNA copy number and DNA hypomethylation might be associated with the upregulation of the CKS2 in LGG. Using the Kaplan-Meier survival analysis and the Cox regression analysis, CKS2 was shown to be independently associated with poor prognosis of LGG patients. Receiver operating characteristic (ROC) analysis revealed that CKS2 could effectively predict the 1-, 3- and 5-year survival rates of LGG patients. Enrichment analyses revealed that CKS2 was mainly involved in the regulation of the cell cycle in LGG. Taken together, our study demonstrated that CKS2 might be a candidate prognostic biomarker for LGG and could predict the survival rates of LGG patients. LGG: lower grade glioma; CKS2: CDC28 protein kinase regulatory subunit 2; TCGA: The Cancer Genome Atlas; CGGA: the Chinese Glioma Genome Atlas; GEO: Gene Expression Omnibus; GEPIA: Gene Expression Profiling Interactive Analysis; TIMER: Tumor Immune Estimation Resource; IHC: immunohistochemistry; qRT-PCR: quantitative real-time polymerase chain reaction; PBS: phosphate buffered saline; DAB: diaminobenzidine tetrachloride; OS: overall survival; CAN: copy number alteration; IDH: Isocitrate dehydrogenase; GSEA: Gene Set Enrichment Analysis; DEG: differentially expressed gene; KEGG: Kyoto encyclopedia of genes and genomes; GO: Gene ontology; BP: biological process; CC: cellular component; MF: molecular function; NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate.
神经胶质瘤占原发性脑恶性肿瘤的最高比例。虽然先前的研究已经证明了 CDC28 蛋白激酶调节亚基 2(CKS2)在各种癌症类型中的作用,但它在低级别神经胶质瘤(LGG)中的功能仍不清楚。本研究旨在描绘 CKS2 在 LGG 中的表达和功能。本研究使用了多个在线数据库,如癌症基因组图谱(TCGA)、中国神经胶质瘤基因组图谱(CGGA)、基因表达谱交互式分析第 2 版(GEPIA2)、肿瘤免疫估计资源第 2 版(TIMER2.0)和基因表达综合数据库(GEO)。免疫组织化学(IHC)用于评估 CKS2 蛋白表达。我们的数据表明,CKS2 在 LGG 组织中的 mRNA 和蛋白质水平均上调,特别是在 3 级神经胶质瘤中。同样,在异柠檬酸脱氢酶 1(IDH1)野生型神经胶质瘤中也有 CKS2 的表达增加。此外,DNA 拷贝数增加和 DNA 低甲基化可能与 LGG 中 CKS2 的上调有关。通过 Kaplan-Meier 生存分析和 Cox 回归分析,表明 CKS2 与 LGG 患者的不良预后独立相关。接受者操作特征(ROC)分析表明,CKS2 可有效预测 LGG 患者的 1 年、3 年和 5 年生存率。富集分析表明,CKS2 主要参与 LGG 中细胞周期的调节。总之,我们的研究表明 CKS2 可能是 LGG 的候选预后生物标志物,并可预测 LGG 患者的生存率。LGG:低级别神经胶质瘤;CKS2:CDC28 蛋白激酶调节亚基 2;TCGA:癌症基因组图谱;CGGA:中国神经胶质瘤基因组图谱;GEO:基因表达综合数据库;GEPIA:基因表达谱交互式分析;TIMER:肿瘤免疫估计资源;IHC:免疫组织化学;qRT-PCR:实时定量聚合酶链反应;PBS:磷酸盐缓冲盐水;DAB:二氨基联苯四氯;OS:总生存期;CAN:拷贝数改变;IDH:异柠檬酸脱氢酶;GSEA:基因集富集分析;DEG:差异表达基因;KEGG:京都基因与基因组百科全书;GO:基因本体论;BP:生物学过程;CC:细胞成分;MF:分子功能;NES:标准化富集分数;NOM:名义;FDR:错误发现率。